(NewsDirect)
Biotechnologycompanies have broken many medical barriers in the past 40 years,harnessing the technological revolution to bring innovative solutionsto medical problems.
One flourishing field in biotech is regenerative medicine, amarket worth $16.9billion in 2021. Regenerative medicine harnesses the body’s amazing ability to heal itself, using cutting-edgetechnology to apply this regenerative power to prompt the body torecover from diseases previously uncured.a
An estimated one-third of Americans would benefit from regenerative therapeuticcures. There are wide applications for such regenerative therapy, withcategories including stem cell research, gene therapy and tissueengineering. Some difficulties for regenerative medicine companiesinclude arduous Food and Drug Administration (FDA) trial processes andthe need for vertical integration of their product development to cutexpenses.
Biotech companies involvedin regenerative medicine include Mesoblast Ltd. (NASDAQ: MESO), Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), LineageCell Therapeutics (NYSE: LCTX) and BioRestorative TherapiesInc. (NASDAQ: BRTX).
Companies Working In The RegenerativeMedicine Industry
Here is a look at some companies looking to be leaders in theregenerative therapy field:
MesoblastLtd. develops novel treatments for back pain and variouscardiovascular conditions. This Australia-based company focusesprimarily on cell therapy solutions, with a mesenchymal lineage stemcell (MSC) technology platform. This develops MSCs, highly multipotentcells taken from healthy bone marrow, and develops treatments fortissue damage, heart disease and more.
LineageCell Therapeutics is a company pioneering cell-based therapiesto treat serious diseases, including ocular disorders and cancer. Ituses its proprietary cell-therapy platform to develop and manufactureself-renewing stem cells into differentiated cells, which can betransplanted to treat problems including cancer or degenerativediseases.
Brainstorm Therapeutics focuses on cell therapies for neurodegenerative diseases. Itsautologous cellular therapeutics platform NurOwn® treats the diseaseby differentiating the patient’s healthy MSCs. Brainstorm’s workmay eventually provide treatments for such neurodegenerative diseasesas Alzheimer’s.
This Company Has Its Own Cell ManufacturingFacility
BioRestorativeTherapies , which primarily develops products using highlytherapeutic adult stem cells, focuses on disc/spine disease andmetabolic disorders. BioRestorative’s brtxDisc program is developinga treatment for the millions of Americans suffering from either chronic or acute back pain. Itsproduct BRTX-100, which uses autologous stem cells to treatdegenerative spinal discs, is in a Phase Two FDA trial.
BioRestorative is alsotackling obesity, which currently affects over 40% of Americans. It is developing the product ThermoStem?, whichharnesses the body’s natural production of healthy brown fat cellsto target patient obesity and other metabolic issues associated withobesity.
BioRestorative believes that its treatments will also helpcondition the body for better future regeneration and responses tomedical treatment. A significant advantage for the company is thevertical integration of development and production it has through itsclinical-grade cell therapy manufacturing facility. This facility,completed in April ,gives BioRestorative control and oversight in the cell manufacturingprocess, apart from the flexibility to make its own decisions and tocorrect quality issues in real-time. Owning the facility mitigates theexpense normally associated with these activities, which is a greatbenefit when conducting FDA trials.
Learn more about BioRestorative by visiting its website .
BioRestorative Therapies was founded by scientists andresearchers committed to developing stem cell therapies to addressunmet needs in patients with highly prevalent conditions.Our advancesin stem cell biology and delivery protocols harbor great promise inconditioning our bodies’ own regenerative potential to treat majordiseases more effectively than current interventions.Today,BioRestorative is actively developing programs that aim todramatically increase quality of care for both (i) chronic back paincaused by disc degeneration, as well as (ii) metabolic disordersincluding obesity and diabetes.
This post contains sponsoredadvertising content. This content is for informational purposes onlyand is not intended to be investing advice.
ContactDetails
Investor Relations
CompanyWebsite
https://www.biorestorative.com/
Copyright (c) 2022 TheNewswire - All rights reserved.